No Data
No Data
Cellectis Presents Research Data On TALEN And TALEB Technologies For Gene And Cellular Therapies At ASGCT Annual Meeting
Monthly Information on Share Capital and Company Voting Rights
Cellectis S.A. Updates UCART Pipeline With Phase 2 Trial Details
European Equities Traded in the US as American Depositary Receipts Track Higher in Monday Trading
JMP Securities Maintains Cellectis(CLLS.US) With Buy Rating, Maintains Target Price $6
Cellectis Reports 2024 Financial Results and Strategic Advances